FindTrial
Sign In

A multicenter, non-therapeutic, interventional, long-term follow-up clinical trial to evaluate the safety of autologous PRAME-directed TCR T cell therapy IMA203 or IMA203CD8 in patients with previously treated, advanced and/or metastatic solid tumors

Status
Not yet recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-525827-25-00
Enrollment
9
Registered
2026-08-21
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumors

Brief summary

Number of patients with delayed adverse events as identified in the Clinical Trial Protocol

Interventions

DRUGIMA203
DRUGIMA203CD8

Sponsors

Immatics US Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Number of patients with delayed adverse events as identified in the Clinical Trial Protocol—

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 22, 2026